What is Aggripal® used for?

Aggripal® is indicated for Major depressive disorder, Generalized anxiety disorder.

Who makes Aggripal®?

Aggripal® is developed by Novartis.

What are the side effects of Aggripal®?

Common side effects include Nausea, Headache, Dizziness, Insomnia, Fatigue.

Last reviewed 2026-04-23 · How we verify

Aggripal®

Novartis · Phase 2 active Biologic

Selective serotonin reuptake inhibitor

Selective serotonin reuptake inhibitor Used for Major depressive disorder, Generalized anxiety disorder.

At a glance

Generic name	Aggripal®
Sponsor	Novartis
Drug class	Selective serotonin reuptake inhibitor
Target	Serotonin transporter
Modality	Biologic
Therapeutic area	Neurology
Phase	Phase 2

Mechanism of action

Aggripal is a selective serotonin reuptake inhibitor (SSRI) that works by increasing the levels of serotonin in the brain, which helps to improve mood and reduce symptoms of depression and anxiety.

Approved indications

Major depressive disorder
Generalized anxiety disorder

Common side effects

Nausea
Headache
Dizziness
Insomnia
Fatigue

Key clinical trials

A Study to Evaluate Safety and Immunogenicity of Trivalent Influenza Vaccine, Formulation 2015 Southern Hemisphere, When Administered to Healthy Adult Subjects. (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Aggripal® CI brief — competitive landscape report
Aggripal® updates RSS · CI watch RSS
Novartis portfolio CI